Premium Nahrungsergänzungsmittel | artgerecht

4-1BB Agonist: Mechanism of Action & Use in Oncology

A 4-1BB agonist is a therapeutic agent that activates the immune receptor 4-1BB, boosting the body's immune response against cancer cells. It is used in oncological immunotherapy.

Regular tips about health Regular tips about health

Things worth knowing about "4-1BB Agonist"

A 4-1BB agonist is a therapeutic agent that activates the immune receptor 4-1BB, boosting the body's immune response against cancer cells. It is used in oncological immunotherapy.

What Is a 4-1BB Agonist?

A 4-1BB agonist is a biopharmaceutical agent that selectively activates the immune receptor 4-1BB (also known as CD137 or TNFRSF9). This receptor belongs to the tumor necrosis factor receptor (TNFR) superfamily and is primarily expressed on activated T lymphocytes (T cells) of the immune system. 4-1BB agonists are used in modern cancer immunotherapy (immuno-oncology) to enhance the body's natural defenses against tumor cells.

Mechanism of Action

The 4-1BB receptor is a costimulatory receptor, meaning it delivers an additional activation signal to T cells after they have recognized a tumor or pathogen. Without this secondary signal, T cells can become anergic (inactive) or undergo programmed cell death.

When a 4-1BB agonist binds to the receptor, it triggers a downstream signaling cascade with the following effects:

T cell proliferation: The number of active cytotoxic T cells (CD8+ T cells) capable of directly killing tumor cells is increased.
Enhanced T cell survival: Activation of 4-1BB inhibits apoptosis (programmed cell death) in T cells, prolonging their lifespan within the tumor microenvironment.
NK cell activation: In addition to T cells, natural killer (NK) cells are also activated, further contributing to anti-tumor immunity.
Memory cell formation: The treatment promotes the development of long-lived memory T cells that can respond more rapidly upon re-exposure to the tumor.

Medical Applications

4-1BB agonists are largely still under clinical development, but several have been investigated in early-phase clinical trials. Their primary areas of application include:

Solid tumors: e.g., melanoma, renal cell carcinoma, non-small cell lung cancer
Hematological malignancies: e.g., diffuse large B-cell lymphoma
Combination therapies: 4-1BB agonists are frequently developed in combination with other immune checkpoint inhibitors (e.g., anti-PD-1, anti-PD-L1) or bispecific antibodies to improve therapeutic efficacy.

Key Agents and Developments

The most notable 4-1BB agonists include:

Urelumab (BMS-663513): A fully human monoclonal antibody evaluated in early clinical trials, but associated with hepatotoxic side effects at higher doses.
Utomilumab (PF-05082566): Another monoclonal antibody with a more favorable safety profile, tested in combination with other therapies.
Bispecific antibodies: Newer agents combine 4-1BB activation with targeting of tumor-specific antigens (e.g., HER2, CD20) to achieve tumor-restricted activation and reduce systemic toxicity.

Side Effects and Safety

Activation of the immune system through 4-1BB agonists can lead to unwanted immune-mediated reactions. Key side effects include:

Hepatotoxicity: Liver toxicity, particularly observed with urelumab at high doses
Systemic inflammatory reactions: Fever, fatigue, cytokine release syndrome
Autoimmune reactions: Similar to other immune checkpoint inhibitors, inflammation in healthy tissues may occur

Research is therefore focused on next-generation antibodies designed to enable more selective activation within the tumor microenvironment, thereby minimizing systemic toxicity risks.

Significance in Modern Oncology

4-1BB agonists represent a promising approach in immuno-oncology. They complement existing strategies such as PD-1/PD-L1 inhibitors and CAR-T cell therapies by directly and durably enhancing effector T cell activity. Particularly in the context of bispecific antibodies and targeted combination therapies, they are attributed with high therapeutic potential.

References

Bartkowiak, T. & Curran, M. A. (2015). 4-1BB Agonists: Multi-Potent Potentiators of Tumor Immunity. Frontiers in Oncology, 5, 117. https://doi.org/10.3389/fonc.2015.00117
Dharmadhikari, B. et al. (2022). CD137 (4-1BB) Agonists in Cancer Immunotherapy: From Bench to Bedside. Frontiers in Immunology, 13, 918960. https://doi.org/10.3389/fimmu.2022.918960
Chester, C., Ambulkar, S. & Kohrt, H. E. (2016). 4-1BB Agonism: Adding the Gas to Take Off Tumor Immunity. Cancer Immunology, Immunotherapy, 65, 1243–1248. https://doi.org/10.1007/s00262-016-1829-2

Building Blocks for a Healthy Life

As an integrated manufacturer, we develop & produce evidence-based, patented, and non-patented formulations. We work exclusively with plant and natural extracts according to the strictest purity & quality standards.
The combination of science & modern technology with the laws of nature creates solutions consistently tailored to humans – for the highest good: health.